Literature DB >> 19821033

Treatment of metastatic colorectal cancer in the elderly.

Hong L Nguyen1, Jimmy Hwang.   

Abstract

OPINION STATEMENT: Metastatic colorectal cancer (CRC) is the second leading cause of cancer related mortality in the United States. The median age of patients at diagnosis is over 70, so as the American population ages, it can be expected that the incidence of CRC will also increase. There is limited prospective data regarding the safety and efficacy of chemotherapy in elderly patients with metastatic CRC. However, the data that are available suggest that elderly patients with a good performance status have a similar likelihood of response to currently available chemotherapy, though perhaps a somewhat higher likelihood of toxicities such as myelosuppression. This paper reviews the available data and recommendations for the treatment of this patient population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19821033     DOI: 10.1007/s11864-009-0111-7

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  29 in total

1.  Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting.

Authors:  Trevor McKibbin; Christopher R Frei; Rebecca E Greene; Peter Kwan; Jody Simon; Jim M Koeller
Journal:  Oncologist       Date:  2008-08-11

2.  Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Authors:  Sharyn D Baker; Jaap Verweij; Eric K Rowinsky; Ross C Donehower; Jan H M Schellens; Louise B Grochow; Alex Sparreboom
Journal:  J Natl Cancer Inst       Date:  2002-12-18       Impact factor: 13.506

Review 3.  Never too old? Age should not be a barrier to enrollment in cancer clinical trials.

Authors:  Matti S Aapro; Claus-Henning Köhne; Harvey Jay Cohen; Martine Extermann
Journal:  Oncologist       Date:  2005-03

4.  A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

Authors:  D J Sargent; R M Goldberg; S D Jacobson; J S Macdonald; R Labianca; D G Haller; L E Shepherd; J F Seitz; G Francini
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

5.  Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

Authors:  Josep Tabernero; Eric Van Cutsem; Eduardo Díaz-Rubio; Andrés Cervantes; Yves Humblet; Thierry André; Jean-Luc Van Laethem; Patrick Soulié; Esther Casado; Chris Verslype; Javier Sastre Valera; Giampaolo Tortora; Fortunato Ciardiello; Oliver Kisker; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

6.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.

Authors:  M Bouchahda; T Macarulla; J P Spano; J B Bachet; G Lledo; T Andre; B Landi; J Tabernero; A Karaboué; J Domont; F Levi; P Rougier
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-08       Impact factor: 6.312

Review 9.  Colorectal cancer in the elderly: is palliative chemotherapy of value?

Authors:  Friedemann Honecker; Claus-Henning Köhne; Carsten Bokemeyer
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.

Authors:  I Chau; A R Norman; D Cunningham; J S Waters; C Topham; G Middleton; M Hill; P J Ross; R Katopodis; G Stewart; J R Oates
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more
  1 in total

1.  Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.

Authors:  Martina Bonifazi; Marta Rossi; Lorenzo Moja; Vincenzo Davide Scigliano; Matteo Franchi; Carlo La Vecchia; Carlo Zocchetti; Eva Negri
Journal:  Oncologist       Date:  2011-12-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.